In addition, roflumilast has been shown to improve peripheral insulin sensitivity in adults with prediabetes and overweight/obesity [123], suggesting that PDE4 may participate in the pathophysiology of peripheral insulin resistance through direct and/or indirect effects. Here, INS is linked to obesity disorder.